NIH R01 · 2024
Targeting immunosuppression of intratumoral CAR T cells
ABSTRACT The clinical benefits of cancer immunotherapies, including adoptive cell transfer (ACT) of chimeric antigen receptor (CAR) T cells, are limited when used against solid tumors. The immuno-suppressive tumor microenvironment (TME) is enriched in cellular components (regulatory T cells, myeloid derived suppressor cells, tumor-associated macrophages, etc) and acellular factors (hypoxia, deficit of nutrients, acidosis, adenosine, etc) that decrease viability and tumoricidal activities of anti-tumor native CD8+ cytotoxic T lymphocytes (CTL) and of therapeutic CAR T cells. Therapeutic neutralization of these factors and components is challenging because of their diversity and redundancy.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.